TerrAscend Q1 2026 slides: margins expand amid Schedule III shift

TerrAscend reported Q1 2026 net revenue of $65.5M, adjusted EBITDA of $17.4M (26.5% margin), and continued strong cash generation with $8.7M operating cash flow and $7.8M free cash flow. Gross margin improved 70 bps to 52.8% and G&A fell to $21.5M, while management raised the strategic upside from DOJ Schedule III rescheduling, which would eliminate 280E tax burden. The company guided Q2 revenue growth of 2% to 3% and highlighted continued portfolio optimization, including Michigan asset sales and accretive M&A focus.

Analysis

The core setup is not the quarter itself; it’s the asymmetric step-change in tax economics if Schedule III survives the legal/political gauntlet. For a levered operator with already-positive cash generation, removing 280E can create a disproportionate EPS/FCF inflection because the benefit drops almost straight to the bottom line rather than requiring volume growth. That makes TSND a cleaner beta expression on federal reform than peers still burning cash, and it should also tighten the spread between stronger operators and marginal operators that depend on equity issuance.

Second-order, the market may be underestimating how rescheduling changes capital allocation across the sector. Lower after-tax earnings and better balance sheets should compress lender spreads, revive sale-leasebacks, and make distressed asset sales more competitive, which actually helps disciplined acquirers with existing operating platforms. TSND’s stated M&A posture matters because it can buy assets when sellers are forced, then re-rate those assets on a lower-tax earnings base; that’s a better use of optionality than pure same-store expansion.

The key risk is timing: the stock can rerate on headlines, but the legal implementation path is likely measured in months, not days, and could be delayed or diluted by litigation, administrative process, or federal inaction. In the interim, the trade is vulnerable to a “sell the reform” response if investors front-run tax savings too aggressively while state pricing remains weak. The other hidden risk is that improved industry profitability may invite more capacity/retail competition, which can cap margin expansion before the tax benefit fully flows through.

Consensus may be too focused on a straight-line multiple expansion and not enough on dispersion. The better trade is not simply long cannabis; it is long the few names with real cash flow, balance sheet flexibility, and acquisition capacity, while avoiding operators whose value case still depends on external capital. If reform slips, TSND likely retraces part of the move, but the downside should be cushioned relative to lower-quality peers because the business already self-funds.

Key Decisions for Investors

• Go long TSND.TO on pullbacks over the next 1-2 weeks; target a 3-6 month hold into any Schedule III implementation headlines, with upside driven by multiple expansion plus tax-rate compression.
• Pair trade: long TSND.TO / short a cash-burning Canadian or U.S. cannabis peer with weaker free cash flow and higher leverage; use this as a dispersion trade over 1-3 months to isolate reform winners from reform hope.
• Buy TSND.TO call spreads 3-6 months out to express policy optionality with defined downside; structure around a catalyst window where headline risk can reprice the sector sharply.
• If TSND.TO gaps higher again, fade part of the move by selling strength or harvesting gains, since the next leg depends on implementation rather than announcement and the stock is vulnerable to a near-term 'buy the rumor, sell the news' pause.
• Overweight acquirers with existing retail footprints versus pure growers in the cannabis basket; the first group should gain the most from lower taxes, cheaper capital, and distressed M&A over the next 6-12 months.